KR960013383A - 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도 - Google Patents

항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도 Download PDF

Info

Publication number
KR960013383A
KR960013383A KR1019950035874A KR19950035874A KR960013383A KR 960013383 A KR960013383 A KR 960013383A KR 1019950035874 A KR1019950035874 A KR 1019950035874A KR 19950035874 A KR19950035874 A KR 19950035874A KR 960013383 A KR960013383 A KR 960013383A
Authority
KR
South Korea
Prior art keywords
vwf
von willebrand
willebrand factor
antithrombotic
combination
Prior art date
Application number
KR1019950035874A
Other languages
English (en)
Inventor
레어스 마르틴
딕나이테 게르하르트
Original Assignee
슈타인, 뵈슬
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈타인, 뵈슬, 베링베르케 아크티엔게젤샤프트 filed Critical 슈타인, 뵈슬
Publication of KR960013383A publication Critical patent/KR960013383A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 혈액 항응고제를 치료제로서 단독으로 사용하거나 피브린 용해소와 함께 사용하는 것과 연관하여 폰 빌레브란트 인자(vWF)- 함유 약물의 투여에 관한 것이다. 환자에게 출혈의 위험을 감소시킬 목적으로 항응고제 치료 및 용해 치료와 동시에 또는 이후 투여할 수 있다. 치료하는 동안 바람직한 효과인 항응고 및/또는 피브린 용해를 바람직하지 않은 출혈과 분리시키는 것이 치료 원리로 서술된다.

Description

항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 항혈전제 및/또는 피브린용해제의 투여로 인해 야기되는 출혈과 관련하여 해독제로서 작용하는 제제를 제조하기 위한, 폰 빌레브란트 인자(vWF) 또는 vWF 활성을 갖는 단편의 용도.
  2. 성분 A로서 항혈전제 및/또는 피브린용해제를 함유하고, 성분 B로서 vWF 또는 vWF 활성을 갖는 단편을 함유하는 약제학적 조성물
  3. 제 2항에 있어서, 개개 성분이 별개의 단일 투여 형태로 존재하는 약제하적 조성물
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950035874A 1994-10-20 1995-10-18 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도 KR960013383A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4437544.1 1994-10-20
DE4437544A DE4437544A1 (de) 1994-10-20 1994-10-20 Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika

Publications (1)

Publication Number Publication Date
KR960013383A true KR960013383A (ko) 1996-05-22

Family

ID=6531287

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950035874A KR960013383A (ko) 1994-10-20 1995-10-18 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도

Country Status (20)

Country Link
US (1) US5571784A (ko)
EP (1) EP0713881A3 (ko)
JP (1) JPH08208504A (ko)
KR (1) KR960013383A (ko)
CN (1) CN1128168A (ko)
AU (1) AU708670B2 (ko)
CA (1) CA2160975A1 (ko)
CZ (1) CZ287878B6 (ko)
DE (1) DE4437544A1 (ko)
FI (1) FI954964A (ko)
HR (1) HRP950525A2 (ko)
HU (1) HU219595B (ko)
IL (1) IL115652A (ko)
NO (1) NO954175L (ko)
NZ (1) NZ280274A (ko)
PL (1) PL183182B1 (ko)
SK (1) SK129695A3 (ko)
TW (1) TW398977B (ko)
UY (1) UY24063A1 (ko)
ZA (1) ZA958838B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
DE102008032361A1 (de) 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
CN102770449B (zh) * 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TWI580423B (zh) * 2013-12-24 2017-05-01 財團法人工業技術研究院 緩解或治療痛風之醫藥組合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
GB8823480D0 (en) * 1988-10-06 1988-11-16 Ciba Geigy Ag Antidote
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4115453A1 (de) * 1991-05-11 1992-11-12 Knoll Ag Neue wirkstoffkombination
US5366869A (en) * 1991-11-08 1994-11-22 Sheldon Goldstein Multiple coagulation test device and method
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
JPH08512291A (ja) * 1993-04-23 1996-12-24 バイオ−テクノロジー・ジェネラル・コーポレーション 血栓溶解の増強方法

Also Published As

Publication number Publication date
HRP950525A2 (en) 1997-04-30
AU3430495A (en) 1996-05-02
PL183182B1 (pl) 2002-06-28
HU219595B (hu) 2001-05-28
IL115652A0 (en) 1996-01-19
EP0713881A2 (de) 1996-05-29
EP0713881A3 (de) 1996-08-21
TW398977B (en) 2000-07-21
CN1128168A (zh) 1996-08-07
NO954175L (no) 1996-04-22
NO954175D0 (no) 1995-10-19
US5571784A (en) 1996-11-05
HUT73762A (en) 1996-09-30
SK129695A3 (en) 1996-10-02
DE4437544A1 (de) 1996-04-25
FI954964A0 (fi) 1995-10-18
FI954964A (fi) 1996-04-21
AU708670B2 (en) 1999-08-12
CZ287878B6 (cs) 2001-03-14
HU9503031D0 (en) 1995-12-28
PL311031A1 (en) 1996-04-29
CA2160975A1 (en) 1996-04-21
IL115652A (en) 2000-08-31
UY24063A1 (es) 1995-10-24
CZ271995A3 (en) 1996-05-15
JPH08208504A (ja) 1996-08-13
NZ280274A (en) 1997-01-29
ZA958838B (en) 1996-05-13

Similar Documents

Publication Publication Date Title
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
BR0207006A (pt) Composição farmacêutica, kit, uso de uma preparação de um fator vii ou polipeptìdeo relacionado ao fator vii em combinação com uma preparação de um fator ix ou polipeptìdeo relacionado ao fator ix, uso de uma composição, método para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente, para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia de um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em um paciente, e para intensificar a formação de coágulo de fibrina em um paciente
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
EA199900499A1 (ru) Фармацевтическая композиция, включающая соединение, обладающее анти-xa активностью, и соединение антагонист агрегации тромбоцитов
KR960013383A (ko) 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도
ES2119165T3 (es) Nueva actividad de cofactor anticoagulante.
Mannucci AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
FI952593A0 (fi) Hyytymistä estävä aine
JP2003528919A5 (ko)
KR920003981A (ko) 항염증성 조성물
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
KR930019224A (ko) 유산 위험 치료제
KR960006920A (ko) 혈액 항응고제에 대한 해독제로서 사용하기에 적합한 약제 및 이의 용도
Gallant A review of dual protease inhibitor therapy
KR950013519A (ko) 골절 예방 및 치료용 약제
Schoenenberger et al. Absence of nitroglycerin-induced heparin resistance in healthy volunteers
Engelberg HEPARIN IN ACUTE MYOCARDIAL INFARCTION—Observations Indicating the Potential Advantages of Using It as the Sole Anticoagulant in Therapy
KR900701322A (ko) 포도필린과 재조합 DNA인간 α인터페론의 배합물로 생식기 우췌를 치료하는 방법
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application